Quick takes on the Social Signals from #ASCO26. 🧬 RASolute-302: @marklewismd 's tweet regarding the standing ovation for RASolute-302 really made that trial stand out. The momentum here was massive, fueled by high expectations from the @RevMedicines PR, #AACR26 presentations,and the high-profile Ben Sasse interviews. ⚔️ PROTEUS: One of the more interesting trials from a social media perspective, as the radiation oncology community on X was highly critical of the trial's surgical paradigm. 🔄 CROWN: Felt a bit like an incredible replay of the Plenary from years ago—steady, practice-confirming data. 🎬 HARMONi-6: Perhaps the most compelling narrative twist. The discussant, Dr. Julie Brahmer, masterfully set up the Plenary audience using The Devil Wears Prada as a research metaphor. It begs the question: Is VEGF back? 🚀 LIBRETTO-432: A massive surprise for many attendees. Lung cancer specialists were thrilled about @LillyOncMed selpercatinib in the adjuvant setting for RET-positive NSCLC. The core takeaway from @christine_lovly presentation was loud and clear: "This is why we test." 🔬 OPTIMA: Really got the breast cancer community excited about using @Veracyte 's test to safely reduce the chemotherapy burden for many of their patients. 📦 WU-KONG28: Had such an interesting vibe. Great data from @Dizal_Global , but it leaves the KOLs asking the same commercial question: Why isn't this readily available to patients in the US yet? Follow the #ASCO26 Pre and Post highlights here: kolpulse.com/kol-pulse-asco2…

RT @Dr_RShatsky: The worst part about the Switch trial proving what knew to be true about payload resistance is that ADCs are basically all…

“Rightly points out lack of crossover in a study with a PFS endpoint as unjust.” — @StephenVLiu on @BenjaminBesseMD's KRASCENDO-1 discussion (@Genentech) #ESMO26 Day 3 roundup: KRASCENDO-1, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012 hubs.ly/Q04CgNjB0